<link rel="stylesheet" href="styles.cf390c6bfbe7555f.css">

New In Silico Insights into the Application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Virus

dc.contributor.authorde Castro, Alexandre A.
dc.contributor.authorAssis, Leticia C.
dc.contributor.authorda Cunha, Elaine F. F.
dc.contributor.authorde Castro Ramalho, Teodorico
dc.contributor.authorLa Porta, Felipe A.
dc.date.accessioned2026-08-18T12:29:19Z
dc.date.issued2022
dc.description.abstractIn this in silico study, different pharmaceutical co-crystals based on (hydroxy)chloroquine with macrolide antibiotics (azithromycin, clarithromycin, or erythromycin A) were analyzed for the first time. These findings present a new molecular perspective and therefore suggest that the combination of (hydroxy)chloroquine/azithromycin, in the stoichiometric ratio of 1:1, as model co-crystal systems has less toxicity and is the most effective for inhibiting the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).eng
dc.formatp. 230-243
dc.identifier.doi10.3390/covid2030018
dc.identifier.issn2673-8112
dc.identifier.obd43882714
dc.identifier.scopus2-s2.0-85191176972
dc.identifier.urihttps://hdl.handle.net/20.500.12603/3110
dc.identifier.wos001178470300001
dc.language.isoeng
dc.noteu autora Assis L. C. doplněn stát. RVeng
dc.peerreviewedyes
dc.project.IDProjekt Excelence PřF UHK
dc.publicationstatuspostprint
dc.publisherMDPI
dc.relation.ispartofCOVID, volume 2, issue: 3eng
dc.relation.publisherversionhttps://www.mdpi.com/2673-8112/2/3/18
dc.rights.accessOpen Access
dc.rights.licenseCC BY
dc.source.urlhttps://www.mdpi.com/2673-8112/2/3/18
dc.subject(hydroxy)chloroquineeng
dc.subjectmacrolide antibioticseng
dc.subjectco-crystalseng
dc.subjectSARS-CoV-2eng
dc.subjectmolecular modellingeng
dc.titleNew In Silico Insights into the Application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Viruseng
dc.typearticle

Soubory